NCT00420420View on ClinicalTrials.gov

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

MK0249

MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.

DRUG

Comparator: Placebo (unspecified)

MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00420420 - MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) | Biotech Hunter | Biotech Hunter